Relationship between the response to CPT-11/platimun regimen and BCRP DNA Metylation in patients with NSCLC recurrence after surgical resection.

Relationship between the response to CPT-11/platimun regimen and BCRP DNA Metylation in patients with NSCLC recurrence after surgical resection. - Relationship between the response to CPT-11/platimun regimen and BCRP DNA Metylation in NSCLC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001064

Enrollment

Registered

2012-12-31

Start date

2007-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

Irinotecan and platinum complex

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NSCLC Post ope recurrence Mesureable lesion Good organ functions

Exclusion criteria

Exclusion criteria: PS more than 2 Previous irinotecan treatment Symptomatic central nervous system metastasis Concomitant malignancies

Design outcomes

Primary

Measure	Time frame
response	—

Secondary

Measure	Time frame
survival, progression free survival, toixicity	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026